Table 4.

Adjusted HRs for 5-year all-cause mortality comparing short (≤10th percentile) with long telomere length (>10th percentile) in lung cancer cases and controls matched to each lung cancer subgroup from the Copenhagen City Heart Study and Copenhagen General Population Study, stratified by time elapsed between sample collection for telomere length measurement and lung cancer diagnosis

Lung cancer casesGeneral population controls
N(Deaths)HRa (95% CI)PqFDRN(Deaths)HRb (95% CI)PPinteractionc
All lung cancers923(769)1.48 (1.18–1.87)6.9 × 10−40.0022,905(429)1.15 (0.87–1.52)0.330.73
NSCLC767(629)1.52 (1.18–1.95)1.2 × 10−30.0032,437(346)0.99 (0.72–1.37)0.960.39
Histology
 Adenocarcinoma440(351)1.48 (1.01–2.16)0.040.061,448(162)1.06 (0.66–1.70)0.800.94
 Squamous211(175)1.45 (0.94–2.25)0.090.11653(120)1.03 (0.58–1.81)0.920.86
SCLC156(140)1.42 (0.74–2.74)0.290.31468(83)1.76 (0.98–3.14)0.060.83
Diagnosed <5 years after sample collection
All lung cancers382(335)1.89 (1.34–2.66)2.9 × 10−40.0011,313(189)0.95 (0.62–1.45)0.820.12
NSCLC319(277)1.98 (1.37–2.86)2.8 × 10−40.0011,093(149)0.68 (0.40–1.16)0.160.01
 Males182(160)1.37 (0.82–2.28)0.230.27583(108)0.62 (0.32–1.19)0.150.04
 Females137(117)4.06 (2.08–7.92)4.0 × 10−50.001510(41)0.77 (0.30–2.01)0.600.33
Histology
 Adenocarcinoma170(145)2.42 (1.37–4.28)2.3 × 10−30.005614(69)0.70 (0.30–1.63)0.400.02
 Squamous86(75)2.19 (1.09–4.41)0.030.05281(54)1.20 (0.53–2.70)0.660.77
SCLC63(58)1.33 (0.45–3.89)0.600.60220(40)1.88 (0.85–4.17)0.120.22
  • aCox models adjusted for age at diagnosis (years), sex, stage (I-IIIA, IIIB-IV, unknown), cigarette pack-years (0, >0–20, 21–40, >40, unknown), body mass index (<18.5, 18.5 to <25, 25 to <30, ≥30, unknown), calibrator lot for the telomere measurement assay, and time elapsed between telomere measurement and lung cancer diagnosis.

  • bCox models adjusted for age at diagnosis (years), sex, cigarette pack-years (0, >0–20, 21–40, >40, unknown), body mass index (<18.5, 18.5 to <25, 25 to <30, ≥30, unknown), calibrator lot for the telomere measurement assay, and time elapsed between blood sample collection and lung cancer diagnosis in the matched case.

  • cPinteraction between case-control status and telomere length was calculated using the likelihood ratio test comparing nested models with and without an interaction term.